Cencora, Inc. (NYSE:COR) Receives $306.33 Average PT from Analysts

Shares of Cencora, Inc. (NYSE:COR - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eleven research firms that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $306.33.

Several equities analysts have issued reports on the stock. Citigroup lifted their price target on shares of Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Wells Fargo & Company raised shares of Cencora from an "equal weight" rating to an "overweight" rating and upped their price target for the company from $274.00 to $337.00 in a report on Tuesday, June 3rd. Robert W. Baird upped their price target on shares of Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Wall Street Zen upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Finally, Bank of America upped their price target on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th.

Insider Activity at Cencora

In other Cencora news, CEO Robert P. Mauch sold 4,969 shares of the business's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $289.33, for a total value of $1,437,680.77. Following the sale, the chief executive officer owned 47,582 shares of the company's stock, valued at $13,766,900.06. The trade was a 9.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Chairman Steven H. Collis sold 14,579 shares of the business's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $292.62, for a total transaction of $4,266,106.98. Following the completion of the transaction, the chairman owned 311,913 shares of the company's stock, valued at approximately $91,271,982.06. This trade represents a 4.47% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 34,127 shares of company stock valued at $9,812,296. Corporate insiders own 10.80% of the company's stock.

Hedge Funds Weigh In On Cencora

Institutional investors and hedge funds have recently modified their holdings of the company. Cornerstone Planning Group LLC lifted its position in Cencora by 106.7% in the first quarter. Cornerstone Planning Group LLC now owns 93 shares of the company's stock valued at $26,000 after acquiring an additional 48 shares during the last quarter. Hoey Investments Inc. purchased a new position in Cencora during the first quarter worth about $28,000. Costello Asset Management INC purchased a new position in Cencora during the first quarter worth about $28,000. Banque Transatlantique SA purchased a new position in Cencora during the fourth quarter worth about $29,000. Finally, SBI Securities Co. Ltd. purchased a new position in Cencora in the fourth quarter valued at about $30,000. Institutional investors and hedge funds own 97.52% of the company's stock.

Cencora Trading Down 0.9%

Shares of Cencora stock traded down $2.83 on Tuesday, hitting $297.33. 1,073,427 shares of the company traded hands, compared to its average volume of 1,509,867. The stock's 50 day moving average price is $291.85 and its 200-day moving average price is $269.23. The company has a current ratio of 0.87, a quick ratio of 0.52 and a debt-to-equity ratio of 6.01. Cencora has a 52 week low of $218.65 and a 52 week high of $309.35. The company has a market cap of $57.63 billion, a PE ratio of 34.49, a PEG ratio of 1.49 and a beta of 0.57.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, topping analysts' consensus estimates of $4.07 by $0.35. The company had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a net margin of 0.55% and a return on equity of 344.71%. Cencora's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.80 earnings per share. Equities research analysts predict that Cencora will post 15.37 EPS for the current year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, May 16th. This represents a $2.20 annualized dividend and a dividend yield of 0.74%. Cencora's dividend payout ratio (DPR) is 25.52%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.